Cytoplasmic expression of estrogen receptor β may predict poor outcome of EGFR-TKI therapy in metastatic lung adenocarcinoma

There is growing evidence that estrogen receptors (ER) are expressed in lung cancer cells, and are able to interact with the epidermal growth factor receptor (EGFR) signaling pathway. However, data on the association between cytoplasmic ER expression and the response to EGFR-tyrosine kinase inhibitors (TKI) treatment are limited. The aim of the present study was to investigate the associations between ERα/ERβ expression and EGFR mutational status and response to TKI treatment in metastatic lung adenocarcinoma. A retrospective study of 126 consecutive patients with lung adenocarcinoma who were diagnosed with stage IV disease and had received EGFR-TKI treatment was conducted. ER expression was detected by immunohistochemistry. EGFR and GTPase KRas (KRAS) mutational statuses were evaluated by denaturing high performance liquid chromatography and PCR-restriction fragment length polymorphism, respectively. In the overall cohort of 126 lung adenocarcinoma samples analyzed, ERα expression in the nucleus of tumor cells was identified in 17 (18.9%) patients, whereas ERβ expression was identified in the nucleus (22/126, 17.5%) and cytoplasm (17/126, 13.5%). The nuclear expression of ERβ was positively associated with the degree of tumor differentiation (P=0.010). EGFR-sensitizing mutations were significantly associated with improved objective response rates (ORR), disease control rates (DCR), median progression-free survival (mPFS) and median overall survival (mOS) (P<0.001; P<0.001; P=0.003; and P=0.026, respectively). Patients with cytoplasmic ERβ expression exhibited non-significant poorer ORR, DCR, mPFS and mOS compared with patients without cytoplasmic ERβ expression (P=0.082; P=0.106; P=0.084; and P=0.119, respectively). However, the significant decrease of ORR, DCR and mPFS was observed in patients with coexisting cytoplasmic ERβ expression and EGFR-sensitizing mutations (P=0.030; P=0.009; and P=0.018, respectively) in comparison with the subgroup with EGFR sensitizing mutations but negative expression of cytoplasmic ERβ. A trend towards shorter mOS was also observed in patients with coexisting cytoplasmic ERβ expression and EGFR-sensitizing mutations (P=0.071). No KRAS mutations were identified in patients with cytoplasmic ERβ expression. Subsequent to adjusting for sex, smoking status and EGFR mutation status, the Cox repression analysis indicated that cytoplasmic expression of ERβ was a negative independent predictor for mPFS in the whole patient cohort (HR=1.870; 95% confidence interval 1.058–3.305; P=0.031). Cytoplasmic ERβ expression was negatively correlated with the efficacy of EGFR-TKI treatment for metastatic lung adenocarcinoma, particularly for patients with coexisting cytoplasmic ERβ expression and EGFR-sensitizing mutations. Cytoplasmic ERβ may be a promising marker to predict the outcome of EGFR-TKI treatment.

[1]  Q. Chu,et al.  Estrogen receptor β1 activation accelerates resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in non-small cell lung cancer. , 2018, Oncology reports.

[2]  Sheng Zhou,et al.  Estrogen promotes tumor metastasis via estrogen receptor beta-mediated regulation of matrix-metalloproteinase-2 in non-small cell lung cancer , 2017, Oncotarget.

[3]  Ming Li,et al.  Correlation between epidermal growth factor receptor mutations and the expression of estrogen receptor-β in advanced non-small cell lung cancer. , 2017, Oncology letters.

[4]  Zhi-Ying Li,et al.  Clinicopathological significance of oestrogen receptor expression in non-small cell lung cancer , 2016, The Journal of international medical research.

[5]  J. Horiguchi,et al.  Prognostic significance of aromatase and estrogen receptor beta expression in EGFR wild-type lung adenocarcinoma. , 2016, American journal of translational research.

[6]  Shuhang Wang,et al.  ERβ localization influenced outcomes of EGFR-TKI treatment in NSCLC patients with EGFR mutations , 2015, Scientific Reports.

[7]  W. Liang,et al.  Patients with Exon 19 Deletion Were Associated with Longer Progression-Free Survival Compared to Those with L858R Mutation after First-Line EGFR-TKIs for Advanced Non-Small Cell Lung Cancer: A Meta-Analysis , 2014, PloS one.

[8]  R. Elashoff,et al.  Abstract 4664: Result of TORI L-03, a randomized, multicenter phase II clinical trial of erlotinib (E) or E + fulvestrant (F) in previously treated advanced non-small cell lung cancer (NSCLC). , 2013 .

[9]  C. Klinge,et al.  Enhanced expression of G-protein coupled estrogen receptor (GPER/GPR30) in lung cancer , 2012, BMC Cancer.

[10]  J. Siegfried,et al.  Combining the Multitargeted Tyrosine Kinase Inhibitor Vandetanib with the Antiestrogen Fulvestrant Enhances Its Antitumor Effect in Non-small Cell Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[11]  Si Yu Wang,et al.  Association between hormone receptor expression and epidermal growth factor receptor mutation in patients operated on for non-small cell lung cancer. , 2011, The Annals of thoracic surgery.

[12]  G. Vlastos,et al.  Lung cancer mortality risk among breast cancer patients treated with anti‐estrogens , 2011, Cancer.

[13]  H. Uramoto,et al.  Expression of estrogen receptor beta predicts a clinical response and longer progression-free survival after treatment with EGFR-TKI for adenocarcinoma of the lung. , 2011, Lung cancer.

[14]  R. Dhir,et al.  Combined Analysis of Estrogen Receptor β-1 and Progesterone Receptor Expression Identifies Lung Cancer Patients with Poor Outcome , 2010, Clinical Cancer Research.

[15]  Leah E Mechanic,et al.  Serum estrogen and tumor-positive estrogen receptor-alpha are strong prognostic classifiers of non-small-cell lung cancer survival in both men and women. , 2010, Carcinogenesis.

[16]  Judith Klein-Seetharaman,et al.  Ligand-independent antiapoptotic function of estrogen receptor-beta in lung cancer cells. , 2010, Molecular endocrinology.

[17]  C. Gomez-Fernandez,et al.  Immunohistochemical Expression of Estrogen Receptor in Adenocarcinomas of the Lung: The Antibody Factor , 2010, Applied immunohistochemistry & molecular morphology : AIMM.

[18]  X. Wang,et al.  Potential Clinical Significance of a Plasma-Based KRAS Mutation Analysis in Patients with Advanced Non–Small Cell Lung Cancer , 2010, Clinical Cancer Research.

[19]  E. Tan,et al.  Correlation between Epidermal Growth Factor Receptor Mutations and Expression of Female Hormone Receptors in East-Asian Lung Adenocarcinomas , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[20]  G. Vlastos,et al.  Reduced Lung Cancer Mortality Risk among Breast Cancer Patients Treated with Anti-Estrogens. , 2009 .

[21]  J. Manson,et al.  Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial , 2009, The Lancet.

[22]  I. Wistuba,et al.  Immunohistochemical Expression of Estrogen and Progesterone Receptors Identifies a Subset of NSCLCs and Correlates with EGFR Mutation , 2009, Clinical Cancer Research.

[23]  Wen Cai,et al.  Regulation of estrogen receptor beta activity and implications in health and disease , 2009, Cellular and Molecular Life Sciences.

[24]  J. Andrade,et al.  Novel actions of estrogen to promote proliferation: Integration of cytoplasmic and nuclear pathways , 2009, Steroids.

[25]  L. Tanoue,et al.  The new lung cancer staging system. , 2009, Chest.

[26]  J. Abbruzzese,et al.  F1000 highlights , 2009, JAMA.

[27]  L. Mao,et al.  Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  J. Siegfried,et al.  Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer. , 2009, Lung cancer.

[29]  A. Parwani,et al.  Estrogen receptor beta functions through nongenomic mechanisms in lung cancer cells. , 2009, Molecular endocrinology.

[30]  T. Oyama,et al.  Association between estrogen receptor-beta expression and epidermal growth factor receptor mutation in the postoperative prognosis of adenocarcinoma of the lung. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Alona Muzikansky,et al.  First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  E. Levin,et al.  Extranuclear steroid receptors: nature and actions. , 2007, Endocrine reviews.

[33]  R. Pietras,et al.  Membrane-Associated Estrogen Receptor Signaling Pathways in Human Cancers , 2007, Clinical Cancer Research.

[34]  M. Fishbein,et al.  Estrogen receptor signaling pathways in human non-small cell lung cancer , 2007, Steroids.

[35]  M. Meyerson,et al.  Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib , 2006, Clinical Cancer Research.

[36]  M. Inoue,et al.  Reproductive factors, hormone use and the risk of lung cancer among middle‐aged never‐smoking Japanese women: A large‐scale population‐based cohort study , 2005, International journal of cancer.

[37]  H. Pass,et al.  Nuclear Estrogen Receptor β in Lung Cancer: Expression and Survival Differences by Sex , 2005, Clinical Cancer Research.

[38]  M. Fishbein,et al.  Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells , 2005, Steroids.

[39]  J. Siegfried,et al.  Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. , 2005, Cancer research.

[40]  J. Siegfried,et al.  Regulation of endogenous gene expression in human non-small cell lung cancer cells by estrogen receptor ligands. , 2005, Cancer research.

[41]  E. Levin.  Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. , 2003, Molecular endocrinology.

[42]  S. Spivack,et al.  Gender-dependent expression of alpha and beta estrogen receptors in human nontumor and tumor lung tissue , 2002, Molecular and Cellular Endocrinology.

[43]  M. Wong,et al.  Adenocarcinoma of the lung in Chinese patients: a revisit and some perspectives from the literature , 2001, Postgraduate medical journal.

[44]  J. Gustafsson,et al.  Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern. , 1997, The Journal of clinical endocrinology and metabolism.

[45]  Daniel Metzger,et al.  Activation of the Estrogen Receptor Through Phosphorylation by Mitogen-Activated Protein Kinase , 1995, Science.

[46]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[47]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[48]  B. Skov,et al.  Oestrogen receptor beta over expression in males with non-small cell lung cancer is associated with better survival. , 2008, Lung cancer.

[49]  J. Siegfried,et al.  Estrogen receptor pathways in lung cancer , 2004, Current oncology reports.

[50]  J. Luketich,et al.  Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. , 2002, Cancer research.